Audrey Echt, MD
MOHS-Micrographic Surgery · Raleigh, NCNPI 1134123847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,017 and has fallen 59.3% since, to $414 in 2025.
Across 186 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$742
- Sun Pharmaceutical Industries Inc.$375
- Amgen$336
- Regeneron Healthcare Solutions, Inc.$295
- Sanofi$260
- LEO Pharma Inc.$206
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $742 |
| Sun Pharmaceutical Industries Inc. | 19 | $375 |
| Amgen | 18 | $336 |
| Regeneron Healthcare Solutions, Inc. | 7 | $295 |
| Sanofi | 8 | $260 |
| LEO Pharma Inc. | 12 | $206 |
| Incyte Corporation | 17 | $203 |
| Novartis | 11 | $191 |
| Arcutis Biotherapeutics, Inc. | 6 | $181 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $145 |
| Verrica Pharmaceuticals Inc. | 1 | $125 |
| Almirall LLC | 6 | $119 |
| Lilly USA, LLC | 5 | $109 |
| Mayne Pharma Commercial LLC | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| UCB, Inc. | 3 | $74 |
| Johnson & Johnson | 3 | $56 |
| Bristol Myers Squibb | 3 | $52 |
| EPI Health, LLC | 2 | $33 |
| Merck | 2 | $23 |
| Prugen, Inc. Pharmaceuticals | 2 | $20 |
| Pfizer | 1 | $20 |
| Aclaris Therapeutics, Inc. | 1 | $19 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Botanix SB Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,812 in reported general payments places this provider in the 75th percentile of 50 mohs-micrographic surgery providers in North Carolina.
See all mohs-micrographic surgery providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Minocycline Hcl | 21 | $439 |
| Mupirocin | 47 | $366 |
| Amoxicillin | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Raleigh
- Eric ChallgrenRaleigh$47K
- Gregory WilmothRaleigh$8K
- Steffany ShearerRaleigh$5K
- Fernando PuenteRaleigh$3K
- Lindsay OsbornRaleigh$678
- Harold RabinovitzRaleigh$623
- Earl BainRaleigh$361
- Tamara HousmanRaleigh$330
- Girish MunavalliCharlotte$118K
- Laura RosenzweigCharlotte$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.